Treatment of anogenital warts.
The treatment of anogenital warts has long been unsatisfactory, with high treatment failure rates and relapse rates. It would seem that a good cell-mediated immune response is important for successful treatment, and the development of immune response modifiers such as Imiquimod give hope for an improved outcome for many patients.
Maw
R D
RD
Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D002424:Caustics / Q000627:therapeutic use; D003218:Condylomata Acuminata / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D003452:Cryosurgery; D004598:Electrosurgery; D006801:Humans; D000077271:Imiquimod; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D007369:Interferon Inducers / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D053685:Laser Therapy; D012008:Recurrence; D017211:Treatment Failure; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000963:Antimetabolites; D002424:Caustics; D007155:Immunologic Factors; D007369:Interferon Inducers; D007641:Keratolytic Agents; D000077271:Imiquimod